Exploring the Effect of Chirality on the Therapeutic Potential of N-alkyl-deoxyiminosugars: Anti-Inflammatory Response to Pseudomonas Aeruginosa Infections for Application in CF Lung Disease

Eur J Med Chem. 2019 Aug 1;175:63-71. doi: 10.1016/j.ejmech.2019.04.061. Epub 2019 Apr 25.

Abstract

In the frame of a research program aimed to explore the relationship between chirality of iminosugars and their therapeutic potential, herein we report the synthesis of N-akyl l-deoxyiminosugars and the evaluation of the anti-inflammatory properties of selected candidates for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF) lung disease. Target glycomimetics were prepared by the shortest and most convenient approach reported to date, relying on the use of the well-known PS-TPP/I2 reagent system to prepare reactive alkoxyalkyl iodides, acting as key intermediates. Iminosugars ent-1-3 demonstrated to efficiently reduce the inflammatory response induced by P. aeruginosa in CuFi cells, either alone or in synergistic combination with their d-enantiomers, by selectively inhibiting NLGase. Surprisingly, the evaluation in murine models of lung disease showed that the amount of ent-1 required to reduce the recruitment of neutrophils was 40-fold lower than that of the corresponding d-enantiomer. The remarkably low dosage of the l-iminosugar, combined with its inability to act as inhibitor for most glycosidases, is expected to limit the onset of undesired effects, which are typically associated with the administration of its d-counterpart. Biological results herein obtained place ent-1 and congeners among the earliest examples of l-iminosugars acting as anti-inflammatory agents for therapeutic applications in Cystic Fibrosis.

Keywords: Cystic fibrosis; NLGase; Polymeric triphenylphosphine; l-Deoxyiminosugars; l-NBDNJ.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / pharmacology
  • Bronchi / immunology
  • Bronchi / microbiology
  • Bronchi / pathology
  • Cystic Fibrosis / complications*
  • Dose-Response Relationship, Drug
  • Humans
  • Imino Sugars / administration & dosage
  • Imino Sugars / chemistry
  • Imino Sugars / pharmacology
  • Imino Sugars / therapeutic use*
  • Inflammation / prevention & control
  • Inhibitory Concentration 50
  • Mice
  • Neutrophils / immunology
  • Pseudomonas Infections / complications*
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / microbiology
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / isolation & purification*
  • Stereoisomerism
  • beta-Glucosidase / antagonists & inhibitors

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Imino Sugars
  • beta-Glucosidase
  • beta-glucosidase 2, mouse